v3.26.1
Note 29 - Segment Reporting
12 Months Ended
May 31, 2026
Notes to Financial Statements  
Segment Reporting [Text Block]

29.

Segment reporting

 

Our Company’s Chief Operating Decision Maker (“CODM”) is the Chairman of the Board of Directors and Chief Executive Officer. The CODM uses segment gross profit for the purpose of resource allocation, assessment of segment performance against determined targets, and in deciding whether to implement cost saving targets. The Company operates in four segments. 1) cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis, 2) beverage operations, which encompasses the production, marketing and sale of beverage products, 3) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers, and 4) wellness products, which encompasses hemp foods and cannabidiol (“CBD”) products. This structure is in line with how our CODM assesses our performance and allocates resources.

 

Operating segments have not been aggregated and no asset information is provided for the segments because the Company’s CODM does not receive asset information by segment on a regular basis. 

 

The following tables reconcile the Company’s segment gross profit to consolidated U.S. GAAP results:

 

  

For the year ended May 31,

 
  

2026

  

2025

  

2024

 

Beverage

            

Net beverage revenue

 $253,976  $240,595  $202,094 

Beverage costs

  162,743   147,591   113,522 

Beverage gross profit

  91,233   93,004   88,572 

Cannabis

            

Net cannabis revenue

  268,342   249,001   272,798 

Cannabis costs

  161,256   150,005   182,594 

Cannabis gross profit

  107,086   98,996   90,204 

Distribution

            

Distribution revenue

  327,244   271,228   258,740 

Distribution costs

  286,589   241,896   230,596 

Distribution gross profit

  40,655   29,332   28,144 

Wellness

            

Wellness revenue

  65,892   60,485   55,310 

Wellness costs

  44,425   41,247   38,879 

Wellness gross profit

  21,467   19,238   16,431 

Total

            

Total revenue

  915,454   821,309   788,942 

Total costs

  655,013   580,739   565,591 

Total gross profit

 $260,441  $240,570  $223,351 

 

Segment costs are comprised of cost of goods sold which include product costs, salaries and an allocation of overhead costs. 

 

The following table reconciles the total segment gross profit to the Company’s consolidated totals:

 

  

For the year ended May 31,

 
  

2026

  

2025

  

2024

 

Gross profit

 $260,441  $240,570  $223,351 
             

Operating expenses:

            

General and administrative

  203,629   167,324   167,358 

Selling

  49,328   56,039   37,233 

Amortization

  19,585   88,616   84,752 

Marketing and promotion

  42,290   37,048   41,933 

Research and development

  361   284   635 

Change in fair value of contingent consideration

  (15,000)  —   (15,790)

Impairment of intangible assets and goodwill

  —   2,096,139   — 

Other than temporary change in fair value of convertible notes receivable

  —   21,661   42,681 

Litigation costs, net of recoveries

  3,902   17,347   8,251 

Restructuring costs

  13,113   34,283   15,581 

Transaction costs (income), net

  6,260   4,534   15,462 

Total operating expenses

  323,468   2,523,275   398,096 

Operating loss

  (63,027)  (2,282,705)  (174,745)

Interest expense, net

  (23,663)  (29,952)  (36,433)

Non-operating income (expense), net

  (1,370)  10,284   (37,842)

Loss before income taxes

  (88,060)  (2,302,373)  (249,020)

Income tax expense (recovery), net

  17,098   (121,017)  (26,616)

Net loss

 $(105,158) $(2,181,356) $(222,404)

 

Channels of cannabis revenue were as follows:

 

  

For the year ended May 31,

 
  

2026

  

2025

  

2024

 

Revenue from Canadian medical cannabis

 $23,726  $24,998  $25,211 

Revenue from Canadian adult-use cannabis

  236,352   224,048   266,846 

Revenue from wholesale cannabis

  7,318   18,207   25,340 

Revenue from international cannabis

  84,910   63,356   53,295 

Less excise taxes

  (83,964)  (81,608)  (97,894)

Total

 $268,342  $249,001  $272,798 

 

There was $nil of cannabis advisory services revenue for the fiscal year ended  May 31, 2026, compared to $1,460 and $1,500 for the fiscal years ended  May 31, 2025 and 2024, respectively. 

 

Geographic net revenue:

 

  

For the year ended May 31,

 
  

2026

  

2025

  

2024

 

USA

 $242,390  $273,695  $233,141 

Canada

  215,661   212,860   243,722 

EMEA

  445,698   323,350   296,450 

Rest of World

  11,705   11,404   15,629 

Total

 $915,454  $821,309  $788,942 

 

Geographic capital assets:

 

  

May 31,

  

May 31,

 
  

2026

  

2025

 

USA

 $207,592  $200,003 

Canada

  245,799   267,458 

EMEA

  202,598   97,371 

Rest of World

  24,236   3,601 

Total

 $680,225  $568,433 

 

Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. For the fiscal years ended  May 31, 2026, 2025 and 2024, there were no major customers representing greater than 10% of our annual revenues.